Abstract
Alzheimers disease (AD) is characterized by selective neuronal cell death, which is probably caused by amyloid b-peptide (Aβ) oligomers and fibrils. We have found that acetylcholinesterase (AChE), a senile plaque component, increases amyloid fibril assembly with the formation of highly toxic complexes (Aβ-AChE). The neurotoxic effect induced by Aβ-AChE complexes was higher than that induced by the Aβ peptide alone as shown both in vitro (hippocampal neurons) and in vivo (rats injected with Ab peptide in the dorsal hippocampus). Interestingly, treatment with Aβ-AChE complexes decreases the cytoplasmic β-catenin level, a key component of Wnt signaling. Conversely, the activation of this signaling pathway by Wnt-3a promotes neuronal survival and rescues changes in Wnt components (activation or subcellular localization). Moreover Frzb-1, a Wnt antagonist reverses the Wnt-3a neuroprotection effect against Aβ neurotoxicity. Compounds that mimic the Wnt signaling or modulate the cross-talking with this pathway could be used as neuroprotective agents for therapeutic strategies in AD patients.
Keywords: ache activity, neurodegenerative processes, brain, amyloid fibrils, hippocampal neurons, signaling pathway, g-catenin, gsk
Current Alzheimer Research
Title: Acetylcholinesterase (AChE) - Amyloid-β-Peptide Complexes in Alzheimers Disease. The Wnt Signaling Pathway
Volume: 1 Issue: 4
Author(s): Nibaldo C. Inestrosa, Soledad Urra and Marcela Colombres
Affiliation:
Keywords: ache activity, neurodegenerative processes, brain, amyloid fibrils, hippocampal neurons, signaling pathway, g-catenin, gsk
Abstract: Alzheimers disease (AD) is characterized by selective neuronal cell death, which is probably caused by amyloid b-peptide (Aβ) oligomers and fibrils. We have found that acetylcholinesterase (AChE), a senile plaque component, increases amyloid fibril assembly with the formation of highly toxic complexes (Aβ-AChE). The neurotoxic effect induced by Aβ-AChE complexes was higher than that induced by the Aβ peptide alone as shown both in vitro (hippocampal neurons) and in vivo (rats injected with Ab peptide in the dorsal hippocampus). Interestingly, treatment with Aβ-AChE complexes decreases the cytoplasmic β-catenin level, a key component of Wnt signaling. Conversely, the activation of this signaling pathway by Wnt-3a promotes neuronal survival and rescues changes in Wnt components (activation or subcellular localization). Moreover Frzb-1, a Wnt antagonist reverses the Wnt-3a neuroprotection effect against Aβ neurotoxicity. Compounds that mimic the Wnt signaling or modulate the cross-talking with this pathway could be used as neuroprotective agents for therapeutic strategies in AD patients.
Export Options
About this article
Cite this article as:
Inestrosa C. Nibaldo, Urra Soledad and Colombres Marcela, Acetylcholinesterase (AChE) - Amyloid-β-Peptide Complexes in Alzheimers Disease. The Wnt Signaling Pathway, Current Alzheimer Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567205043332063
DOI https://dx.doi.org/10.2174/1567205043332063 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Possible Usefulness of Growth Hormone/Insulin-like Growth Factor-I Axis in Alzheimer’s Disease Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets The Pulse of Drug Development for Alzheimers Disease
Reviews on Recent Clinical Trials Editorial (Hot Topic: Biomedical Engineering Imaging)
Current Pharmaceutical Biotechnology Does the Association Between Anxiety and Parkinsons Disease Really Exist? A Literature Review
Current Psychiatry Reviews Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Patterns of Cognitive Impairment in Neurological Disease
Current Psychiatry Reviews Interleukin-4-Induced Oxidative Stress Via Microglial NADPH Oxidase Contributes to the Death of Hippocampal Neurons In Vivo
Current Aging Science Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia
Current Alzheimer Research Agents Complexing Copper as a Therapeutic Strategy for the Treatment of Alzheimers Disease
Current Alzheimer Research Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology Curcuminoids and Novel Opportunities for the Treatment of Alzheimer's Disease: Which Molecules are Actually Effective?
Current Molecular Pharmacology AMPK Function in Aging Process
Current Drug Targets New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Cognition Therapeutics (Guest Editor: Miao-Kun Sun)]
Current Drug Targets - CNS & Neurological Disorders Conference Report:5<sup>th</sup> International Conference on Nanotek & Expo, Nov 16-18, 2015, San Antonio TX, USA
CNS & Neurological Disorders - Drug Targets Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment
Current Alzheimer Research Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology